000			02105nam a2200445 i 4500
999			_c279807 _d279807
001			on1086389949
003			OCoLC
005			20190318103535.0
006			m o d f
007			cr gn|||||||||
008			190220s2019 dcua ob f000 0 eng c
040			_aPUCPR _beng _erda _epn _cGPO _dMvI
042			_apcc
043			_an-us---
074			_a1019-C-01 (online)
086	0		_aY 4.C 73/8:115-96
088			_aSerial no. 115-96 (United States. Congress. House. Committee on Energy and Commerce)
099			_aY 4.C 73/8:115-96
110	1		_aUnited States. _bCongress. _bHouse. _bCommittee on Energy and Commerce. _bSubcommittee on Health,
245	1	0	_aExamining implementation of the Compounding Quality Act : _bhearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Fifteenth Congress, second session, January 30, 2018.
264		1	_aWashington : _bU.S. Government Publishing Office, _c2019.
300			_a1 online resource (vi, 286 pages) : _billustrations
336			_btxt
337			_bc _2rdamedia
338			_bcr _2rdacarrier
500			_a"Serial no. 115-96."
500			_aCRDP Program record.
504			_aIncludes bibliographical references.
588			_aDescription based on online resource; title from PDF title page (govinfo, viewed Feb. 20, 2019).
776	0	8	_iPrint version: _aUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health. _tExamining implementation of the Compounding Quality Act _w(OCoLC)1085900766
856	4	0	_uhttps://purl.fdlp.gov/GPO/gpo116408
050		4	_aKF27 _b.E553 2018e
610	1	0	_aUnited States. _tDrug Quality and Security Act.
610	1	0	_aUnited States. _bFood and Drug Administration _xRules and practice.
650		0	_aDrugs _xDosage forms _xGovernment policy _zUnited States.
650		0	_aPharmaceutical industry _xGovernment policy _zUnited States.
650		0	_aDrug adulteration _zUnited States _xPrevention.
655		7	_aLegislative hearings. _2lcgft
942			_2sudocs _c8